Medical centers across the U.S. are recruiting Hispanic and Non-Hispanic Caucasian patients for a new hepatitis C treatment study. The Hepatitis C Latino Study will assess response to standard interferon/ribavirin treatment in Latino patients versus non-Latino Caucasian patients with chronic hepatitis C. The study will measure the efficacy and safety of the combination therapy in patients. Over the course of 48 weeks, researchers will examine data gathered from over 500 study participants, to help determine whether there is a significant connection between race and effectiveness of the treatment.
The study is sponsored by the research and pharmaceutical company Hoffmann-La Roche. Approximately 60 medical centers in California, Florida, New York, Texas and several other states are currently enrolling patients. Eligibility criteria, study locations and other information can be found at www.clinicaltrials.gov/ct/gui/show/NCT00107653 or by calling 800-526-6367.